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Abstract
Introduction: There is a jaw cancer that develops in children five to eight years old in holoendemic malaria
regions of Africa, associated to malaria and Epstein Barr virus infections (EBV). This malignancy is known as
endemic Burkitt’s lymphoma, and histopatologically is characterized by a starry sky appearance. To date, no
histopathologic expression of Burkitt’s lymphoma has been reported in non-genetically manipulated experimental
animals. The purpose of the study is to describe the case of a mouse immune to Plasmodium yoelii yoelii (Pyy) that
developed a Burkitt’s lymphoma-like neoplasm after repeated malaria infections.
Results: Immune mouse 10 (IM-10) developed neoplasms at eight months of age, after receiving three Pyy
inoculations. At autopsy eight subcutaneous tumors were found of which the right iliac fosse tumor perforated the
abdominal wall and invaded the colon. The histopathologic study showed that all neoplasms were malignant
lymphomas of large non-cleaved cells also compatible with variants or previous states of development of a
Burkitt’s lymphoma-like. The thymus, however, showed a typical starry sky Burkitt’s lymphoma-like neoplasm.
Conclusions: Neoplasm development in CD1 mouse is associated to both, immunity against malaria and
continuous antigenic stimulation with living parasites.
It is the first observation of a histopathologically expressed Human Burkitt’s lymphoma-like neoplasm in a non-
genetically manipulated mouse.
Chronic immune response associated to neoplasms development could probably be not an exclusive expression of
malaria-host interaction but, it could be a pattern that can bee applied also to other agent-host interactions such
as host-bacteria, fungus, virus and other parasites.
Introduction
Malaria in the tropics is a problem of worldwide concern,
because of the millions of persons falling ill and dead each
year [1] and, the children suffering of Burkitt’s lymphoma
have to be counted among them. Dr. Denis Burkitt first
described this neoplasm in Ugandan children in 1957 [2].
Today this tumor is known as Burkitt’sl y m p h o m a( B L )
which corresponds to a neoplasia of B cells that grows
mainly in the jaw, and some times also in ovary and testis.
Its major incidence occurs in African children five to eight
years old in a geographical band of latitude 10 degrees
north and 10 degrees south the equator, also called the
Burkitt’s lymphoma belt or the malaria belt, because it
coincide with holoendemic malarious territories i.e. with
areas of the highest malaria transmission intensity. Three
BL types are distinguished, the endemic form, the sporadic
and the associated to HIV infections. The endemic type
occurs in Africa holoendemic malaria territories, the
sporadic elsewhere out of Africa and the associated to
HIV infection is everywhere Africa included [3].
Just after BL discovery it was clear to Dalldorf [4] that
the geographical association between malaria and the BL
incriminated in some way the malaria parasites with the
neoplasia development, although there were no argu-
ments to substantiate this idea. Few years later Antony
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tic cells of Burkitt’s lymphoma [5], which is known since
then as Epstein Barr virus (EBV). The discovery of the
virus opened controversial opinions between those that
f a v o rm a l a r i ap a r a s i t e so rE B V ,a si m p l i c a t e di nt h e
malignant transformation of B lymphocytes. Arguments
favoring one or the other microorganism has come and
gone but still today discussion has not reach an end.
Methods
Mice
C D 1m a l em i c eo f2 0 - 2 5gb o d yw e i g h tw e r eu s e da s
experimental animals and for Pyy strain maintenance.
Certified CD1 Charles River strain was used, under the
guidelines of the Faculty of Medicine Ethics Commis-
sion and the Mexican Official Norm NOM-062-ZOO-
1999 on Technical Specifications for Breeding, Care and
Uses of Laboratory Animals.
Parasite
The lethal strain of Plasmodium yoelii yoelii (Pyy) was
used and maintained by mouse-to-mouse passages. For
maintenance, 10 μL of Pyy infected blood was poured into
5m lo fs a l i n ea n d0 . 5m lo ft h i ss u s p e n s i o nw e r ei n o c u -
lated intraperitoneally to each mouse
Immune mouse
For a mouse to be regarded in a status of sterile immu-
nity it has to be able to overcome a primary Pyy infection
that is usually lethal to non-immune mice, without ther-
apy intervention. The mouse has to resist a Challenge
after a month’s survival to the primary infection and its
blood has to be no infective to non- immune mice, after
a week of the challenge.
Epstein Barr virus (EBV)search
T h ep r e s e n c eo fE B Vi nt h et u m o ra sw e l la si nt h ea n i -
mal’s blood, was studied by two procedures: Polimerase
chain reaction (PCR) and Electron microscopy (EM). For
EM, a tumor sample was processed: first, it was fixed with
2.5% glutaraldehide mixed with sodium cacodylate 0.1 M,
and then post fixed with 1% osmium tetra oxide and dehy-
drated in ethyl alcohol concentrations from 50%, 70%,
80%, 90% and 100%. Then the fragment was treated with
propylene oxide for 30 min and then mixed with Epon,
and included overnight. After that, the fragment was cut
and the specimen supported on a 30 μm mesh and stained
with 4% uranyl acetate and 0.35% lead acetate, according
to Glavert [6]. The specimens were observed in a Jeol elec-
tron microscope JEM-1200 Ex II.
For PCR analysis, DNA was extracted and purified
from another fragment of the tumor and a blood sample,
using the chloroform method. Whole DNA of the
mouse’s blood and tumor samples and an EBV DNA
control sample were tested by PCR to search for EBV in
an assay with primers specific for the EBNA1 gene:
5-TCATCATCATCCGGGTCTCC-3 and 5-CCTA-
CAGGGTGGAAAAATGGC-3 [7].
The CD1 Burkitt’s lymphoma model
Nowadays, the experimental study of BL is limited by
the lack of an animal model to reproduce and study the
disease. Hori M [8] studied more than 30,000 cases of
lymphomas in NFS.V+ mice and 400 in AKXD mice,
without finding histological features comparable to
human BL. According to Kovalchuk [9], tumors with
histological and phenotypic features of BL have never
been described in mice. However, he experimentally
reproduced BL in the mice, although his mice had to be
humanized by genetic manipulations to enable them to
express BL.
These experiments were done in CD1 male mice and
their first malaria infection was induced at about two
months of age. Due to the lethality of the Pyy strain, the
first infection decided the fate of mice that can only be
death or survival. As a rule, most of them died, but excep-
tionally some of them survive. If they survive they acquire
a sterile immune state. When parasites enter again, a tem-
poral infection with very low parasitemia is established;
usually reaching in its peak no more than 2%, and there-
after the parasites disappear at variable lapses of time, from
three to twelve days with a mean of 5.5 days. After this
time no parasites are found by blood microscopy or sub-
inoculation of blood or organs into non-immune mice.
We observed that those few CD1 mice that naturally sur-
vived and acquired sterile immunity against the lethal strain
of Plasmodium yoelii yoelii (Pyy) were in risk of developing
a neoplasm, if antigenic stimulation (re-infections) with liv-
ing parasites was repeated several times. We observed a
CD1 mouse immune to Pyy that developed eight subcuta-
neous and one peritoneal lymphocytic lymphomas (also
compatible with variant of Burkitt’s lymphoma) and one
more in the thymus with the histopathologic features of a
human Burkitt’s Lymphoma-like neoplasm. This mouse
identified as immune mouse 10 (IM-10) was part of a
group of 13 immune mice which developed different types
of neoplasia during these experiments, and whose entire
observations will be published elsewhere.
Neoplasm developed by CD1 immune mouse 10
The immune mouse 10
On third October 2005 an experiment was started in
which 22 mice were inoculated by the intra-peritoneal
route with a cultivated strain of Pyy, on an infectivity
test. After one month’s observation, blood infection by
the cultivated Pyy was not detected in any of the mice. In
order to see the response of these mice to the virulent
parasite strain from which the cultivated forms arose,
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infection was followed. Ten days later, all mice had died
except two of them. On December 13
th both surviving
mice were challenge with Pyy infected blood. Parasites
were not detected in their blood after the third day and,
their blood was not infective by transfer to non-immune
mice after the fourth day, thus both mice survived and
were qualified as immune. One of these mice was the
immune mouse 10 (IM-10). On the 23rd of February
(2006) IM-10 was inoculated with Pyy infected blood
when participating in a Pyy phagocytosis experiment. On
June 12
th a neoplasia was detected in the abdomen of
IM-10. On 26
th June the neoplasia had grown up and a
new tumor was detected in the neck. On 15
th August
IM-10, another neoplasm of the neck was detected up
the sternum measuring about two and a half cm long,
apparently conformed by a single movable mass (see
Figure 1). The abdominal neoplasm was also movable but
adhered to deep tissues, and another two neoplastic
bodies grew in both iliac fosses, however, IM-10 looked
not much affected. Blood samples stained with Giemsa
and sub inoculation of its blood into non-immune mice,
showed that this mouse was free of malaria infection. On
October 14
th , as IM-10 was adynamic, and his facial and
shoulder’s hair was falling it was decided that it partici-
pated in a last phagocytosis experiment before it was
autopsied. The experiment consisted on inoculation of
Pyy infected blood to IM-10 by intra-peritoneal route,
leaving it to rest during four days and then (October
18
th) its blood was transferred to two recipient mice to
detect infection and, then it was inoculated with Pyy
infected blood again, leave for one hour and then intra-
peritoneal exudates were collected under anesthesia,
to check for phagocytosis of malaria parasites by macro-
phages, thereafter IM-10 was sacrificed by an overdose of
anesthesia and autopsied.
Autopsy
eight neoplastic masses were observed (Figure 2), four of
them located around the maxilla and the front neck, one
on each axilla and one on each iliac fossa. The tumors
in the neck were adhered to the surface of the thyroid
gland. Each single tumor was between 1.7 and 1.8 cm
long, profusely vascularized. The four neoplastic masses
of the neck were covered together by a single transpar-
ent membrane, with adherence at some points to muscle
and skin, branched blood vessels joined the tumors with
the thyroid gland. The subcutaneous neoplasms at both
iliac fossa measure 1.5 cm long and both were adhered
to the skin and well vascularized. The one on the right
perforated the abdominal wall and was seen fussed to a
portion of the colon, it measured 6.5 cm in its whole
length (Figure 3) and was not vascularized, it was the
tumor localized in the abdomen. Both iliac fossa tumors
were well vascularized and encapsulated. Both axilla
tumors were also encapsulated and with no apparent
invasion to other tissues. Liver, spleen and thymus were
hypertrophied, kidneys with no macroscopic pathology,
suprarenal glands were rough on their surface and aug-
mented in size, brain, heart and lungs were macroscopi-
cally normal.
Histopathology
Organs with no proliferative lesions
Lung
It shows pneumonitis with inflammatory or neoplastic
infiltrate surrounding the veins and bronchioles. Arteries
not seemed to be affected.
Figure 1 Immune Mouse 10, before autopsy.S e et h et u m o r
running along the front neck that somewhat deform the face.
Figure 2 Immune Mouse 10, first plane autopsy. It shows four
tumoral masses along front neck, two on each side, covering most
of the thyroid gland of which just a portion is seen at the center.
Another four neoplastic bodies are seen distributed on right and
left axilla and right and left iliac fosse. Low central abdomen shows
another mass behind the abdominal wall.
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Congested, showing multi-nucleated gigantic cells con-
taining malaria pigment, and big nuclei containing chro-
matin grains. Nuclei were apparently non-neoplastic.
Brain
Signs of hypoxia, increased population of lymphocytes in
the meningeal layer, without signs of meningitis, with no
malaria pigment nor lesions in vessels, mostly normal.
Organs with proliferative lesions
Left iliac fossa’s neoplastic tissue
Hyper-chromatic lymphoid cells with medium size cyto-
plasm and open nuclei with coarse chromatin and some
cells showing one or two prominent nucleoli, six to
seven mitosis (shown at × 40 magnification) that suggest
cells under mitoses processes of a malignant lymphoma
of large non cleaved cells (Figure 4).
Colon neoplastic tissue
A uniform cell layer was found with very similar cellular
composition to those found in the above lesion, but also
presented an influx of lymphoma cells and other white
cells running in the lumen of a blood vessel (Figure 5).
Malignant lymphoma of large non cleaved cells.
Kidney
The tissue surrounding renal tubules was infiltrated by
lymphoma cells. This process was focalized.
Thymus
Neoplastic tissue was rejecting normal thymus tissue
( F i g u r e6 ) .T h en e o p l a s t i ct i s s u es h o w sav e r yt y p i c a l
starry sky characteristic of human Burkitt’s lymphoma
cells seem uniform with very small variations in size and
form, and very little cytoplasm, with round central
nuclei, of well define borders, with coarse chromatin
and with one or two basophile nucleoli (small non
cleaved cells), it call our attention the normal isolated
macrophages with phagocyted cellular debris in its cyto-
plasm that conforms the islands of the starry sky (for
more detail see Figure 7).
From all tumors and organs observed, just the thymus
presented the characteristic morphology of the human Bur-
kitt’s lymphoma-like neoplasm. All other tumors had fea-
tures that suggest lesions of malignant lymphoma of large
non cleaved cells, also compatible with variants or previous
states of development of a Burkitt’s lymphoma-like.
Epstein Barr virus search
The PCR analysis detected EBV in the control sample
but did not detect EBV DNA in the tumor, nor either in
the blood. Electron microscopy did not detect EBV par-
ticles and not any other particle suspicious to be of viral
origin.
Blood parasites Search
The blood taken from IM-10 four days before the last
inoculation of Pyy did not contained malaria parasites,
Figure 3 Immune Mouse 10, second plane authopsy. It shows
the abdominal mass neoplasm fussed with the colon, which can be
identified by the feces dark spots.
Figure 4 Immune mouse 10, left iliac fosse neoplasic tissue.
Histopathology. Hyper-chromatic lymphoid cells that correspond to
cells under mitoses processes of a malignant lymphocytic
lymphoma poorly differentiated. Hematoxylin & Eosin (× 40).
Figure 5 Immune mouse 10, colon fussed neoplasic tissue.
Histopathology. Flux of necrotic and pycnotic cells running inside a
vein whit no erythrocytes visible. H&E (× 40).
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non-immune mice.
Malaria, Epstein Barr Virus infection and Burkitt’s
lymphoma natural history in African Children
In order to explain our views about the emergence of
malignant cells in mouse’s tissues, which acquire the
histological features of a BL and its correlation with the
human BL, a remembrance of the human life cycle of
people living in the holoendemic malaria regions of
Africa, and their association with malaria and EBV
infection, seems to be necessary.
A baby borne in Africa holoendemic malaria regions is
coming to a world in which she or he has to fight to
survive to malaria infections. If these babies are born
free of malaria infection, their prime malaria infection is
mostly experienced during the first year of life, usually
after the first six months of age and from here on they
are exposed to repeated infections for the rest of their
lives. In some countries they receive an average of one
infected bite each 3.6 days all year round [10], while in
others 25 infective bites per month are expected [11]. In
this mosquito biting atmosphere, P. falciparum morbid-
ity reach a peak at around the age of five, leveling off
after 10 years old [12]. Children thus live two stages in
their life (in relation to malaria), one between the ages
of one to five, in which they build an immune state to
be protected, no against malaria infection but against
clinical malaria, so this is a pre-immune stage. The sec-
ond stage comprehend ages from 5 to 10 in which most
surviving children have already acquired a state of clini-
cal immunity protection [13] so it is an immune stage,
although protective immunity to malaria infection
would never be acquired [14].
EBV lives in the B lymphocytes of 95% of human
beings whatever they reside and, in 100% of holoen-
demic malaria residents in Africa. Primary infection by
EBV is acquired at different ages in Africa, the babies
first infection may be acquired when passing through
the vagina during delivery [15], or in the firsts months
of life through salivary transmission, with minor or no
clinical signs. Primary EBV infection induces cellular
and humoral responses, which control the infection but
do not eliminate it, passing to a latent state during all
their lives [16].
Although children that survive and reach the second
stage will continue being infected by malaria parasites
and keep EBV latent infections for all their life, they do
not usually die from any of these two infections, how-
ever, they are exposed to develop other diseases in
which the immune system is involved as result of their
continuous antigenic stimulation, such as the nephrotic
syndrome [17], hyperreactive malaria splenomegaly [18],
as well as the same BL. This is suggestive that possibly
some other diseases linked with the continuous activa-
t i o no ft h ei m m u n es y s t e mb yt h em a l a r i ap a r a s i t e sa r e
still to be recognized.
To better understand the elements that precede the
emergence of Burkitt’s lymphoma of humans and Burkitt’s
lymphoma-like in the rodents, we produce a list of some of
these elements that may be compared to make some light,
as follows:
1) BL and BL-like neoplasm of the mouse are associated
to their specific malaria parasite infection, Plasmodium
falciparum in humans and P. yoelii yoelii in the mouse.
2) P. falciparum infection in humans, and P. yoelii in
the mouse have two or more possible outcomes. Whereas
in the mouse the outcomes can be death or sterile immu-
nity, in humans the outcomes can be death, clinical
immunity and some others immunity linked pathologies.
3) In humans just about 1% of those exposed to infec-
tions by P. falciparum die, whereas 99% acquire clinical
Figure 6 Immune mouse 10, thymus tissue, Histopathology.
Normal tissue is rejected by the tumor. Neoplastic tissue shows a
very typical starry sky, characteristic of human burkitt’s lymphoma.
H&E (× 10).
Figure 7 Immune mouse 10, thymus tissue. Histopathology.
Typical image of a starry sky as seen in human Burkitt’s lymphoma
(× 40).
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infection and just about 0.2% acquires sterile immunity.
4) In humans immunity is reached after about five
long years of exposure to transmission of the parasites,
while in the mice immunity or death is defined with the
first infection, in about a month in this experiments.
5) Endemic BL of humans and BL-like neoplasm of
the mouse, both are linked to an immune response
against their own malaria parasites.
6) Endemic BL in humans appear once an immune sta-
tus against P. falciparum is established, after years of con-
tinuous antigenic stimulation, and the stimulation persist,
while in the mouse it appears after a sterile immunity has
been developed and the antigenic stimulus persists.
7) In humans the endemic BL is accompanied by P.
falciparum infection and almost invariably by EBV
infection, while in the mouse BL-like the infection by P.
yoelii is not accompanied by EBV infection because this
virus does not infect laboratory rodents nor has this
ever been reported in these animals [19], see table 1.
The view of these elements suggest that three compo-
nents have to be considered when thinking on the neo-
plasm genesis: the malaria parasite, the EBV and the
immune response of the host, persistently activated by
both malaria parasites and EBV, and possibly by other
agents.
BL is a neoplasia of B cells and all Burkitt lymphoma
cells invariably present translocation of c-myc/IgH genes
as a landmark character, independently of the BL type to
which it belongs. Therefore, for B cells to be transformed
into malignancy the c-myc genes have to be activated and,
for this to happen, translocation of c-myc/IgH has to take
place. It becomes clear that it is of the uppermost impor-
t a n c et od e f i n ew h a tc a u s e st h et r a n s l o c a t i o ni nt h eB
cells. Most people working on the field would incriminate
EBV as the cause of translocations [20,21] and, many
others would involve the association of malaria infection
to the emergence of BL, and to the translocation of c-myc.
However, there are no definite evidences that one or the
other agent is the direct cause of c-myc translocation
[22,23]. Furthermore BL may exist in absence of malaria,
and EBV infections [24,25], therefore, if Burkitt’sl y m -
phoma exist in absence of malaria and EBV infection,
translocation of c-myc/IgH is not carried out by any of
these two agents (as it occurs in most sporadic Burkitt’s
lymphoma), then If we discard both transmissible agents,
as direct cause of c-myc translocation, just immunity,
would explain the genesis of BL. Although malaria para-
sites and EBV are playing a very important role for the B
cells to be transformed, they are not “per se” the direct
cause of translocation, another factor involved is necessary
and this factor may well be the host himself through his
immune response.
Translocation of c-myc/IgH-Burkitt’s lymphoma as
autoimmune-disease
Regarding the immune response as the central element
in translocation, then BL can develop in absence of
malaria parasites and EBV, and both could be sup-
planted for other agents either chemical or biological,
that chronically activate the host immune response. The
facts available today would incriminate malaria parasites
and EBV as the biological agents involved in endemic
BL, as the constantly repeated antigen stimulating fac-
tors of the immune response, that seems to lead to c-
myc translocation, B cells malignization and genesis of
Burkitt’s lymphoma.
In principle, it would appear difficult to sustain that
the host immune system is the cause of neoplasm gen-
esis through its own cellular components, however,
t h e r ei sas t o r yo fa tl e a s t3 3y e a r st h a tl i n k si m m u n i t y
to malignancy, which probably started when Philip J.
Fialkow [26] realized that immunologic mechanisms
induce chromosomal aberrations which in turn play a
role in the genesis of malignancy, additionally he noticed
that increased frequency of neoplasms were associated
to a variety of autoimmune disorders, e.g. autoimmune
hemolytic anemia and lymphoid neoplasia. Experiments
of the time indicated that lymphoid neoplasms arise
with considerable frequency in animals injected with
immunologically competent foreign lymphoid cells. He
declared that autoimmune disease and the neoplasm
may both be manifestations of the same process, and he
cited Dameshek, who refers to the autoimmune disease
and neoplasm as immunoproliferative disorders, suggest-
ing that the only essential difference between the auto-
i m m u n ed i s e a s ea n dt h em a l i g n a n c yi st h eg r e a t l y
expanded cell mass in the latter.
Current concepts to reconstruct the processes that lead
to an efficient adaptive immune response, sustain that
the antigenic stimulation of naive B cells triggers a
refined mechanism to accomplish the hallmark of adap-
tive immunity, characterized by its delicate specificity for
Table 1 Comparison between endemic human Burkitt’
lymphoma and Burkitt’s lymphoma-like of the mouse
Endemic BL BL-like
host species Humans CD1 mice
infecting Plasmodium P. falciparum P. yoelii yoelii
outcome of infection death orclinical
immunity
death orsterile
immunity
population survival 99% 0.2%
time to reach
immunity
about five years about one month
immune state
necessary
Yes yes
virus association Epstein-Barr virus not known
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of the immunoglobulin genes through class switch
recombination (CSR) and somatic hyper mutation (SHM)
which are initiated by activation-induced cytidine deami-
nase (AID) [27]. Once a B cell responds to the antigen
stimulation, before becoming an antibody producing
plasma cell, some rearrangements and sequence modifi-
cations in the Ig genes are needed in order to be able to
produce an isotype of antigen receptor that perfectly
matches the recognized antigen. These processes are
done through CSR or SHM and in both it is initiated by
the enzyme AID mainly produced by the B cell germinal
centers. This enzyme generates DNA double strand
breaks, which needs to be repaired to tailor the gene to
codify a protein that precisely matches the antigen recog-
nized. At the end of the process the new tailored B cell
become a clone of memory B cells that will reproduce
when stimulated by the same antigen. To the B cell, these
processes are normal in the way of establishing an
immune response and, occur each time a naïve B cell
recognizes a new antigen. When AID mediated lesions
are improperly repaired it can promote chromosomal
translocations of which the most studied is the c-myc/
IgH t(8;14) that deregulates c-Myc giving rise to neoplas-
tic cells in human BL [28-33].
According with the immune panorama above
described, in malaria, as result of the prime infection, it
w o u l db ee x p e c t e dt h a tap o p u l a t i o no fh i g h l ys p e c i f i c
memory B cells should be produced, so that when a new
host-parasite interaction take place, and the parasite
bears the same antigen, the memory cells would be awa-
ken to generate an immune response to eliminate the
parasites. The experience dictates that an individual may
develop a malaria infection (symptomatic or not) when-
ever the parasites that reach that individual expresses
antigenic variants different to that of the previous infec-
tion. In that case, the B cells of that individual have to
repeat all the processes of genomic rearrangements each
time the individual enters in contact with a parasite pos-
s e s s i n gan e wv a r i e t yo fa n t i g e n s ,g i v i n go p p o r t u n i t yf o r
the B cells to produce chromosomal translocations and
transform B cells into malignancy as much as the inten-
sity of parasite contacts increase.
A person living in malaria holoendemic areas, in Africa,
has the chance of receiving and infective bite once a day
or a week and each infected mosquito inoculates from 10
to 100 sporozoites per bite. In nature the human beings
do not build a protective immune response against spor-
ozoites, so each time an infected mosquito bites, invasion
of the liver cells takes place. This amount of sporozoites
seems to be too small a stimulus to evoke an efficient
protective immune response. Experimentally, to produce
a protective immune response, about a 1000 mosquito
bites are necessary [34].
Persistent transmission of malaria parasites through
mosquito bites means a persistent antigenic stimulation
of B cells in germinal centers, and a persistent genome
breaking and repair, and therefore a constant exposure
to the risk of an anomalous repair and c-myc/IgH trans-
location and c-myc activation.
With the analysis done, it seems reasonable to propose
that neither malaria parasites nor EBV are the onco-
genes per se, but that the neoplasm arises secondary to
the host’s immune response to a persistent and chronic
antigenic stimulation. That immune stimulation may
come from malaria parasites, from EBV, from a joint sti-
mulation of both, or possibly from any other agent that
causes a similar type of constant antigenic stimulation.
In humans, BL arise at the peak of the immune
response after 5 to 8 years of persistent stimulation by
the malaria parasites and reactivations of EBV infection.
Certainly, not all children submitted to this rhythm of
constant malaria re-infection develop BL, in fact, just
one to five out of 100,000 children will develop BL,
which suggests that the immune cells response to
malaria differs among the children population and only
some few of them respond in a way that permits a pos-
sible malignant transformation of their B cells. In the
mouse model, BL arose after a state of sterile immunity
was acquired and antigenic stimulation persisted, and
also after stimulation was done at the peak of an
immune response. In the CD1 mice the amount of ani-
mals that develop sterile immunity after malaria infec-
tion is meager, and BL was unexpectedly observed in
one out of 13 neoplasia cases.
Conclusions
The CD1 mice may develop a neoplasm histopathologi-
cally indistinguishable of human Burkitt’s lymphoma, if
the mouse is in a sterile immune status against malaria
parasites and, continues to receive antigenic stimulation
with living parasites, as in the model Plasmodium yoelii
yoelii-CD1 mouse, here described.
It is the first time that a neoplasia with the histo-
pathological features of human Burkitt’s lymphoma is
observed in a non-genetically manipulated mouse.
There is a link between immunity to malaria parasites
and human Burkitt’s lymphoma-like development, in
absence of Epstein Barr virus, in this rodent model.
It is therefore proposed, that the immune response of
the host against malaria parasites is the genesis of Bur-
kitt’s lymphoma, and that parasites and viral agents are
just inducers of the host response. In other words, it is a
neoplasm made by the host himself. If those neoplasms
are produced by ourselves as response to a chronic expo-
sure to parasites, it could be a biological process not only
limited to malaria parasites-host interactions, but also to
the persistent and chronic interactions of the host
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gus, virus and other parasites, with the condition that the
host’s immune response share the same or a similar con-
struction of the response to malaria, i.e. persistent, con-
stant and chronic stimulation of the immune system with
antigenic variants of the same agent’s species.
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